|
Gene: UBA52 |
Gene summary for UBA52 |
Gene summary. |
Gene information | Species | Human | Gene symbol | UBA52 | Gene ID | 7311 |
Gene name | ubiquitin A-52 residue ribosomal protein fusion product 1 | |
Gene Alias | CEP52 | |
Cytomap | 19p13.11 | |
Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | P62987 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7311 | UBA52 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 1.19e-08 | -1.11e-01 | -0.0809 |
7311 | UBA52 | RNA-P8T2-P8T2-3 | Human | Lung | AIS | 4.37e-06 | -2.21e-01 | -0.1284 |
7311 | UBA52 | C04 | Human | Oral cavity | OSCC | 8.24e-65 | 4.23e+00 | 0.2633 |
7311 | UBA52 | C21 | Human | Oral cavity | OSCC | 1.81e-73 | 3.36e+00 | 0.2678 |
7311 | UBA52 | C30 | Human | Oral cavity | OSCC | 2.44e-113 | 5.16e+00 | 0.3055 |
7311 | UBA52 | C38 | Human | Oral cavity | OSCC | 3.19e-69 | 4.11e+00 | 0.172 |
7311 | UBA52 | C43 | Human | Oral cavity | OSCC | 2.21e-125 | 3.69e+00 | 0.1704 |
7311 | UBA52 | C46 | Human | Oral cavity | OSCC | 3.87e-68 | 3.11e+00 | 0.1673 |
7311 | UBA52 | C51 | Human | Oral cavity | OSCC | 5.80e-83 | 3.53e+00 | 0.2674 |
7311 | UBA52 | C57 | Human | Oral cavity | OSCC | 3.46e-47 | 3.03e+00 | 0.1679 |
7311 | UBA52 | C06 | Human | Oral cavity | OSCC | 2.29e-68 | 3.76e+00 | 0.2699 |
7311 | UBA52 | C07 | Human | Oral cavity | OSCC | 7.08e-44 | 3.67e+00 | 0.2491 |
7311 | UBA52 | C08 | Human | Oral cavity | OSCC | 1.55e-84 | 2.95e+00 | 0.1919 |
7311 | UBA52 | C86 | Human | Oral cavity | OSCC | 1.27e-30 | 2.23e+00 | 0.161 |
7311 | UBA52 | C09 | Human | Oral cavity | OSCC | 3.03e-50 | 2.47e+00 | 0.1431 |
7311 | UBA52 | LN22 | Human | Oral cavity | OSCC | 5.62e-74 | 3.41e+00 | 0.1733 |
7311 | UBA52 | LN38 | Human | Oral cavity | OSCC | 5.89e-81 | 3.65e+00 | 0.168 |
7311 | UBA52 | LN46 | Human | Oral cavity | OSCC | 5.82e-40 | 2.91e+00 | 0.1666 |
7311 | UBA52 | LP15 | Human | Oral cavity | LP | 5.84e-55 | 3.67e+00 | 0.2174 |
7311 | UBA52 | LP16 | Human | Oral cavity | LP | 5.18e-23 | 2.40e+00 | 0.1055 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
GO:00096368 | Breast | Precancer | response to toxic substance | 31/1080 | 262/18723 | 1.18e-04 | 2.12e-03 | 31 |
GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
GO:000963613 | Breast | IDC | response to toxic substance | 44/1434 | 262/18723 | 6.33e-07 | 3.00e-05 | 44 |
GO:000218124 | Breast | DCIS | cytoplasmic translation | 82/1390 | 148/18723 | 2.21e-53 | 1.25e-49 | 82 |
GO:000963623 | Breast | DCIS | response to toxic substance | 42/1390 | 262/18723 | 1.76e-06 | 6.56e-05 | 42 |
GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
GO:00096369 | Cervix | CC | response to toxic substance | 52/2311 | 262/18723 | 3.34e-04 | 3.52e-03 | 52 |
GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
GO:000963614 | Cervix | HSIL_HPV | response to toxic substance | 24/737 | 262/18723 | 1.14e-04 | 2.36e-03 | 24 |
GO:000218125 | Cervix | N_HPV | cytoplasmic translation | 42/534 | 148/18723 | 2.61e-30 | 1.19e-26 | 42 |
GO:000963624 | Cervix | N_HPV | response to toxic substance | 27/534 | 262/18723 | 9.00e-09 | 1.71e-06 | 27 |
GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
GO:0009636 | Colorectum | AD | response to toxic substance | 88/3918 | 262/18723 | 1.12e-06 | 3.72e-05 | 88 |
GO:00021811 | Colorectum | SER | cytoplasmic translation | 102/2897 | 148/18723 | 1.38e-48 | 8.49e-45 | 102 |
GO:00096361 | Colorectum | SER | response to toxic substance | 71/2897 | 262/18723 | 8.63e-07 | 4.07e-05 | 71 |
GO:00021812 | Colorectum | MSS | cytoplasmic translation | 108/3467 | 148/18723 | 1.78e-47 | 1.11e-43 | 108 |
GO:00096362 | Colorectum | MSS | response to toxic substance | 73/3467 | 262/18723 | 1.26e-04 | 1.94e-03 | 73 |
GO:00021813 | Colorectum | MSI-H | cytoplasmic translation | 100/1319 | 148/18723 | 1.50e-79 | 8.31e-76 | 100 |
GO:00021814 | Colorectum | FAP | cytoplasmic translation | 76/2622 | 148/18723 | 3.31e-27 | 2.03e-23 | 76 |
Page: 1 2 3 4 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0301018 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0517118 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0513118 | Breast | Precancer | Shigellosis | 44/684 | 247/8465 | 3.91e-07 | 6.86e-06 | 5.26e-06 | 44 |
hsa0516718 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0413716 | Breast | Precancer | Mitophagy - animal | 15/684 | 72/8465 | 5.22e-04 | 3.93e-03 | 3.01e-03 | 15 |
hsa0301019 | Breast | Precancer | Ribosome | 80/684 | 167/8465 | 7.33e-44 | 2.32e-41 | 1.77e-41 | 80 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0517119 | Breast | Precancer | Coronavirus disease - COVID-19 | 81/684 | 232/8465 | 3.74e-32 | 2.36e-30 | 1.81e-30 | 81 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0513119 | Breast | Precancer | Shigellosis | 44/684 | 247/8465 | 3.91e-07 | 6.86e-06 | 5.26e-06 | 44 |
hsa0516719 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0413717 | Breast | Precancer | Mitophagy - animal | 15/684 | 72/8465 | 5.22e-04 | 3.93e-03 | 3.01e-03 | 15 |
hsa0501224 | Breast | IDC | Parkinson disease | 107/867 | 266/8465 | 2.57e-39 | 8.36e-37 | 6.26e-37 | 107 |
hsa0301024 | Breast | IDC | Ribosome | 83/867 | 167/8465 | 6.07e-39 | 9.87e-37 | 7.38e-37 | 83 |
hsa0517124 | Breast | IDC | Coronavirus disease - COVID-19 | 86/867 | 232/8465 | 1.50e-28 | 9.72e-27 | 7.27e-27 | 86 |
hsa0502223 | Breast | IDC | Pathways of neurodegeneration - multiple diseases | 116/867 | 476/8465 | 3.63e-20 | 1.18e-18 | 8.82e-19 | 116 |
hsa0513124 | Breast | IDC | Shigellosis | 47/867 | 247/8465 | 1.78e-05 | 2.00e-04 | 1.49e-04 | 47 |
hsa0516723 | Breast | IDC | Kaposi sarcoma-associated herpesvirus infection | 38/867 | 194/8465 | 5.87e-05 | 5.96e-04 | 4.46e-04 | 38 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
UBA52 | SNV | Missense_Mutation | c.268N>T | p.Asn90Tyr | p.N90Y | P62987 | protein_coding | deleterious(0) | possibly_damaging(0.857) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
UBA52 | SNV | Missense_Mutation | c.310N>T | p.His104Tyr | p.H104Y | P62987 | protein_coding | deleterious(0.04) | benign(0.317) | TCGA-E9-A1R4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | |
UBA52 | SNV | Missense_Mutation | novel | c.170N>T | p.Ser57Leu | p.S57L | P62987 | protein_coding | deleterious(0.04) | benign(0.3) | TCGA-C5-A1MP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
UBA52 | SNV | Missense_Mutation | rs563262392 | c.316N>T | p.Arg106Cys | p.R106C | P62987 | protein_coding | tolerated(0.16) | benign(0) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UBA52 | SNV | Missense_Mutation | c.212N>C | p.Leu71Ser | p.L71S | P62987 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
UBA52 | SNV | Missense_Mutation | c.281N>C | p.Met94Thr | p.M94T | P62987 | protein_coding | tolerated(0.06) | benign(0.006) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
UBA52 | SNV | Missense_Mutation | c.22N>A | p.Leu8Ile | p.L8I | P62987 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
UBA52 | SNV | Missense_Mutation | novel | c.77T>C | p.Val26Ala | p.V26A | P62987 | protein_coding | deleterious(0) | possibly_damaging(0.595) | TCGA-AP-A1DR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
UBA52 | SNV | Missense_Mutation | novel | c.72N>T | p.Glu24Asp | p.E24D | P62987 | protein_coding | tolerated(0.62) | benign(0.148) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
UBA52 | SNV | Missense_Mutation | c.124N>G | p.Arg42Gly | p.R42G | P62987 | protein_coding | deleterious(0) | benign(0.071) | TCGA-BK-A0CB-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |